# IPATential150 (NCT03072238)

> Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: ipatasertib plus abiraterone
- Indication: previously untreated metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03072238
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Metastatic Prostate Cancer
- Interventions: Ipatasertib; Abiraterone; Placebo; Prednisone/Prednisolone
- Enrollment: 1101
- Primary outcome: Investigator-assessed Radiographic Progression-free Survival (rPFS), Per Prostate Cancer Working Group 3 (PCWG3) Criteria in Phosphatase and Tensin Homolog (PTEN) Loss Population
- Primary outcome: Investigator-assessed rPFS, Per PCWG3 Criteria in ITT Population

## Indexed commentary on IPATential150 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 11
- YouTube: 9
- Podcasts: 4
- Bluesky threads: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=ipatential150-nct03072238

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03072238", "email": "<work email>"}; the inbox owner confirms by the emailed link.